Dual targeting antibodies (Huang et al., 2020; Long et al., 2024) combining specificities for HER2 and B7-H3, or HER2 and EGFR may be more specific than bispecific antibodies targeting HER2 alone and thereby reduce on-target off-tumor side effects. The gene discussed is EGFR; the disease is neoplasm.